Wanzhen Xu Selected Research

Lipopolysaccharides

4/2023

Sulforaphane reduces lipopolysaccharide-induced inflammation and enhances myogenic differentiation of mouse embryonic myoblasts via the toll-like receptor 4 and NLRP3 pathways.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wanzhen Xu Research Topics

Disease

4	Neoplasms (Cancer) 01/2024 - 01/2017
2	Glioma (Gliomas) 01/2024 - 01/2022
2	Glioblastoma (Glioblastoma Multiforme) 01/2017 - 01/2017
1	Neoplasm Metastasis (Metastasis) 01/2024
1	Inflammation (Inflammations) 04/2023
1	Sepsis (Septicemia) 04/2023
1	Sarcopenia 04/2023
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 02/2021
1	Subdural Hematoma (Subdural Hemorrhage) 02/2021
1	Hematoma 02/2021
1	Astrocytoma (Pilocytic Astrocytoma) 01/2017

Drug/Important Bio-Agent (IBA)

3	Proteins (Proteins, Gene)FDA Link 01/2024 - 01/2022
1	Cholinergic ReceptorsIBA 01/2024
1	Interleukin-6 (Interleukin 6)IBA 01/2024
1	Messenger RNA (mRNA)IBA 01/2024
1	RNA (Ribonucleic Acid)IBA 01/2024
1	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2024
1	sulforaphaneIBA 04/2023
1	LipopolysaccharidesIBA 04/2023
1	Toll-Like Receptor 4IBA 04/2023
1	InflammasomesIBA 04/2023
1	ChemokinesIBA 01/2022
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022
1	Chemokine ReceptorsIBA 01/2022
1	Temozolomide (Temodar)FDA LinkGeneric 01/2017
1	DNA (Deoxyribonucleic Acid)IBA 01/2017
1	Aurora Kinase AIBA 01/2017
1	N-phthaloylglutamic acidIBA 01/2017

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 01/2024 - 01/2017
1	Immunotherapy 01/2024
1	Craniotomy 02/2021